Top 10 Value Stocks To Invest In Right Now

tags:CF,EMD,CPRX,AGEN,ADUS,UBSH,DVAX,MCFT,ZBH,SM,

Frontier Capital Management Co. LLC acquired a new position in Seattle Genetics, Inc. (NASDAQ:SGEN) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 59,263 shares of the biotechnology company’s stock, valued at approximately $3,934,000.

Several other large investors have also recently made changes to their positions in SGEN. BlackRock Inc. raised its stake in shares of Seattle Genetics by 9.5% in the first quarter. BlackRock Inc. now owns 8,492,963 shares of the biotechnology company’s stock worth $444,521,000 after purchasing an additional 736,469 shares during the last quarter. Nexthera Capital LP purchased a new position in shares of Seattle Genetics in the first quarter worth about $18,998,000. Wells Fargo & Company MN raised its stake in shares of Seattle Genetics by 337.2% in the first quarter. Wells Fargo & Company MN now owns 306,681 shares of the biotechnology company’s stock worth $16,051,000 after purchasing an additional 236,538 shares during the last quarter. First Trust Advisors LP raised its stake in shares of Seattle Genetics by 18.0% in the second quarter. First Trust Advisors LP now owns 1,042,574 shares of the biotechnology company’s stock worth $69,216,000 after purchasing an additional 159,401 shares during the last quarter. Finally, UBS Group AG raised its stake in shares of Seattle Genetics by 108.4% in the first quarter. UBS Group AG now owns 256,549 shares of the biotechnology company’s stock worth $13,428,000 after purchasing an additional 133,450 shares during the last quarter.

Top 10 Value Stocks To Invest In Right Now: CF Industries Holdings, Inc.(CF)

Advisors' Opinion:

• [By Max Byerly]

  CF Industries (NYSE:CF) had its target price trimmed by Bank of America from $40.00 to $38.00 in a report published on Friday. The brokerage currently has an underperform rating on the basic materials company’s stock.

• [By Joseph Griffin]

  Canaccord Genuity Group Inc (TSE:CF) Director Dvaipayan Ghose sold 20,000 shares of Canaccord Genuity Group stock in a transaction on Thursday, June 14th. The stock was sold at an average price of C$7.17, for a total transaction of C$143,400.00.

• [By Chris Lange]

  The stock posting the largest daily percentage loss in the S&P 500 ahead of the close was CF Industries Holdings, Inc. (NYSE: CF) which fell about 3% to $43.04. The stock's 52-week range is $27.27 to $46.20. Volume was about 2.6 million compared to the daily average volume of 2.6 million.

Top 10 Value Stocks To Invest In Right Now: Western Asset Emerging Markets Income Fund, Inc(EMD)

Advisors' Opinion:

• [By Joseph Griffin]

  Emerald Crypto (EMD) is a proof-of-work (PoW) coin that uses the
  Scrypt hashing algorithm. Its launch date was June 16th, 2013. Emerald Crypto’s total supply is 19,117,129 coins. Emerald Crypto’s official Twitter account is @Emerald_Crypto and its Facebook page is accessible here. Emerald Crypto’s official website is www.emeraldcrypto.de.

Top 10 Value Stocks To Invest In Right Now: Catalyst Pharmaceuticals, Inc.(CPRX)

Advisors' Opinion:

• [By Lisa Levin] Gainers Sigma Labs, Inc. (NASDAQ: SGLB) shares rose 90.9 percent to $2.52. Sigma Labs demonstrated proof of concept for closed loop quality control during metal additive manufacturing. Oragenics, Inc. (NYSE: OGEN) shares surged 58.4 percent to $1.9005 after the company’s AG013 for oral mucositis in head and neck cancer patients showed favorable safety profile in mid-stage OM study. Dick's Sporting Goods, Inc. (NYSE: DKS) shares climbed 23.2 percent to $37.5370 after the company reported upbeat Q1 earnings and raised FY18 earnings outlook. Summer Infant, Inc. (NASDAQ: SUMR) rose 21.9 percent to $1.17 after announcing commitment for $60 million credit facility from Bank of America and $17.5 million term loan from Pathlight Capital. TapImmune, Inc. (NASDAQ: TPIV) jumped 18.8 percent to $4.87. WBB Securities upgraded TapImmune from Speculative Buy to Buy. Movado Group, Inc. (NYSE: MOV) gained 17.2 percent to $49.45 after the company reported better-than-expected Q1 results and raised its guidance. ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) jumped 16.2 percent to $7.96. BTIG Research initiated coverage on ASLAN Pharmaceuticals with a Buy rating. Legacy Reserves LP (NASDAQ: LGCY) rose 15.5 percent to $5.6011. InspireMD, Inc. (NYSE: NSPR) gained 13.3 percent to $1.36 following PR announcing sustained benefit of CGuard EPS. Immutep Limited (NASDAQ: IMMP) shares climbed 13.2 percent to $2.7724 after the company reported new data from its ongoing TACTI-mel Phase I trial, which evaluated the combination of eftilagimod alpha, its lead compound, with Merck & Co., Inc. (NYSE: MRK)'s Keytruda in unresectable or metastatic melanoma patients, who have had a suboptimal response or had disease progression with keytruda monotherapy.. SpartanNash Co (NASDAQ: SPTN) rose 12.2 percent to $21.20 after the company reported upbeat earnings for its first quarter on Tuesday. Amtech Systems, Inc. (NASDAQ: ASYS) rose 12.1 percent to
• [By Joseph Griffin]

  Cantor Fitzgerald assumed coverage on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report issued on Thursday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $8.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 153.97% from the stock’s current price.

• [By Shane Hupp]

  Cantor Fitzgerald assumed coverage on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report issued on Thursday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $8.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 153.97% from the stock’s current price.

• [By Joseph Griffin]

  BidaskClub downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a sell rating to a strong sell rating in a report published on Wednesday morning.

• [By Stephan Byrd]

  BidaskClub cut shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a hold rating to a sell rating in a report published on Tuesday.

  CPRX has been the subject of several other research reports. HC Wainwright set a $6.00 target price on Catalyst Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 22nd. Zacks Investment Research raised Catalyst Pharmaceuticals from a hold rating to a buy rating and set a $3.25 target price for the company in a research report on Monday, August 13th. Oppenheimer started coverage on Catalyst Pharmaceuticals in a research report on Thursday, July 12th. They issued a buy rating and a $6.00 target price for the company. Cantor Fitzgerald started coverage on Catalyst Pharmaceuticals in a research report on Friday, September 21st. They issued an overweight rating for the company. Finally, Piper Jaffray Companies started coverage on Catalyst Pharmaceuticals in a research report on Friday, September 7th. They issued an overweight rating and a $5.00 target price for the company. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of Hold and an average price target of $5.61.

• [By Joseph Griffin]

  Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) have received a consensus rating of “Buy” from the seven research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $6.25.

Top 10 Value Stocks To Invest In Right Now: Agenus Inc.(AGEN)

Advisors' Opinion:

• [By Shane Hupp]

  Shares of Agenus (NASDAQ:AGEN) dropped 9.8% during trading on Monday following a dissappointing earnings announcement. The stock traded as low as $3.30 and last traded at $3.32. Approximately 2,421,286 shares changed hands during mid-day trading, an increase of 53% from the average daily volume of 1,586,724 shares. The stock had previously closed at $3.68.

• [By George Budwell]

  Shares of the small-cap biotech Agenus (NASDAQ:AGEN) reversed its year-long down trend by gaining a stately 20.1% last month, according to data from S&P Global Market Intelligence. What sparked this marked turnaround?

• [By George Budwell]

  The small-cap immuno-oncology company Agenus (NASDAQ:AGEN) and the inhaled insulin company MannKind Corporation (NASDAQ:MNKD) are prime examples of this phenomenon. Even though both of these companies have been in existence for over two decades, these two particular biotechs have failed to bring a product to market capable of generating a significant revenue stream. As a result, these two companies have essentially been forced to wipe out their early shareholders through serial dilution.

• [By Cory Renauer]

  Harnessing the power of the immune system to fight cancer is a big deal and Agenus Inc. (NASDAQ:AGEN) looks like a great way to follow the trend. This stock trades like a small-cap biotech, but a couple of candidates coming through its pipeline could help push annual revenue past the $1 billion mark. Plus, by this time next year, the company could have half a dozen or so new candidates in clinical trials.

Top 10 Value Stocks To Invest In Right Now: Addus HomeCare Corporation(ADUS)

Advisors' Opinion:

• [By Ethan Ryder]

  BidaskClub upgraded shares of Addus Homecare (NASDAQ:ADUS) from a buy rating to a strong-buy rating in a report published on Saturday.

  Several other equities analysts have also recently weighed in on the stock. Stephens set a $56.00 price target on shares of Addus Homecare and gave the company a buy rating in a research report on Monday, April 2nd. Robert W. Baird set a $43.00 price target on shares of Addus Homecare and gave the company a hold rating in a research report on Wednesday, March 14th. ValuEngine raised shares of Addus Homecare from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research cut shares of Addus Homecare from a buy rating to a strong sell rating in a research report on Monday, June 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $51.00.

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on Addus Homecare (ADUS)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  Addus HomeCare (NASDAQ:ADUS) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

Top 10 Value Stocks To Invest In Right Now: Union Bankshares Corporation(UBSH)

Advisors' Opinion:

• [By Shane Hupp]

  Union Bankshares (NASDAQ:UBSH) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a report issued on Thursday.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on Union Bankshares (UBSH)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Motley Fool Staff]

  Union First Market Bankshares (NASDAQ:UBSH) Q2 2018 Earnings Conference CallJul. 18, 2018 9:00 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator 

• [By Shane Hupp]

  Union Bankshares (NASDAQ:UBSH) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Thursday.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Union Bankshares (UBSH)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Value Stocks To Invest In Right Now: Dynavax Technologies Corporation(DVAX)

Advisors' Opinion:

• [By George Budwell]

  Shares of immuno-oncology and next-generation vaccine-maker Dynavax Technologies Corporation (NASDAQ:DVAX) lost 10.5% of their value in September, according to data from S&P Global Market Intelligence. What went wrong for the drugmaker last month?

• [By Lisa Levin] Gainers ARMO BioSciences, Inc. (NASDAQ: ARMO) shares rose 67.5 percent to $49.96 in pre-market trading after Eli Lilly and Company (NYSE: LLY) announced plans to acquire ARMO BioSciences for $50 per share. Turtle Beach Corporation (NASDAQ: HEAR) rose 62.8 percent to $11.30 in pre-market trading after the company reported Q1 results and raised its FY18 outlook. vTv Therapeutics Inc. (NASDAQ: VTVT) rose 23.4 percent to $2.11 in pre-market trading following announcement that the company will pre-specify new subgroup with the FDA and report Phase 3 Part B results in June. Resonant Inc. (NASDAQ: RESN) rose 19.1 percent to $5.00 in pre-market trading after reporting Q1 results. RXi Pharmaceuticals Corporation (NASDAQ: RXII) rose 17.7 percent to $2.39 in pre-market trading following Q1 results. Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 15.2 percent to $2.20 in pre-market trading after French company Total announced plans to acquire 25 percent stake in Clean Energy Fuels for $83.4 million. Everspin Technologies, Inc. (NASDAQ: MRAM) rose 14.6 percent to $8.50 in pre-market trading after the company reported strong results for its first quarter. Carvana Co. (NYSE: CVNA) shares rose 11 percent to $27.50 in pre-market trading after reporting upbeat Q1 sales. Sunrun Inc. (NASDAQ: RUN) rose 8.9 percent to $10.70 in pre-market trading following upbeat quarterly earnings. MediciNova, Inc. (NASDAQ: MNOV) rose 8.1 percent to $11.35 in pre-market trading after the company announced opening of Investigational New Drug Application for MN-166 (ibudilast) in glioblastoma. New Gold Inc. (NYSE: NGD) shares rose 7.7 percent to $2.65 in pre-market trading after the company reported that its President and CEO Hannes Portmann left the company. The company named Raymond Threlkeld as successor. Otter Tail Corporation (NASDAQ: OTTR) shares rose 7.4 percent to $46.60 in the pre-market trading session. Himax Technologies, Inc. (NASDAQ: HIMX) shares rose
• [By Joseph Griffin]

  Dynavax Technologies (NASDAQ:DVAX) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

• [By Neha Chamaria, George Budwell, and Rich Duprey]

  Each of these situations -- and more like them -- could throw up great opportunities for long-term investors. Not one to miss them, we asked three Motley Fool contributors to hunt up an unappreciated stock that they believe deserves more love. They came up with some really interesting names, including Illinois Tool Works (NYSE:ITW), ShotSpotter (NASDAQ:SSTI), and Dynavax Technologies Corporation (NASDAQ:DVAX).

Top 10 Value Stocks To Invest In Right Now: MCBC Holdings, Inc.(MCFT)

Advisors' Opinion:

• [By Shane Hupp]

  Paloma Partners Management Co trimmed its position in MCBC Holdings Inc (NASDAQ:MCFT) by 14.7% in the second quarter, HoldingsChannel reports. The institutional investor owned 15,754 shares of the company’s stock after selling 2,715 shares during the quarter. Paloma Partners Management Co’s holdings in MCBC were worth $456,000 as of its most recent SEC filing.

• [By Logan Wallace]

  Get a free copy of the Zacks research report on MCBC (MCFT)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Lisa Levin] Gainers The Trade Desk, Inc. (NASDAQ: TTD) jumped 36.2 percent to $71.82 after the company reported upbeat results for its first quarter. The company also issued strong second-quarter and FY18 sales guidance. WideOpenWest, Inc. (NYSE: WOW) jumped 30.4 percent to $8.80 after the company reported Q1 results. MoSys, Inc. (NASDAQ: MOSY) shares surged 28.6 percent to $1.9541 after the company reported better-than-expected Q1 results and issued strong Q2 forecast. Boxlight Corporation (NASDAQ: BOXL) gained 24 percent to $6.39. Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares gained 19.1 percent to $24.60. Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced that the Endocrinologic and Metabolic Drugs Advisory Committee, which met to discuss the safety and efficacy of subcutaneously injected volanesoren solution for patients with familial chylomicronemia syndrome, voted 12-8 to support its approval. Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 17 percent to $10.31 after reporting Q3 results. ArcBest Corporation (NASDAQ: ARCB) gained 16.8 percent to $43.1457 after reporting upbeat quarterly earnings. Amtech Systems, Inc. (NASDAQ: ASYS) rose 16.2 percent to $8.60. Amtech posted Q2 earnings of $0.19 per share on sales of $32.783 million. Identiv, Inc (NASDAQ: INVE) surged 14.4 percent to $3.8450 following Q1 results. Omeros Corporation (NASDAQ: OMER) shares rose 14.3 percent to $18.43 following Q1 results. VivoPower International PLC (NASDAQ: VVPR) gained 11.5 percent to $2.71. Intersections Inc. (NASDAQ: INTX) gained 11.4 percent to $2.55 after reporting Q1 results. Noodles & Company (NASDAQ: NDLS) shares rose 10.9 percent to $8.65 following Q1 results. Voyager Therapeutics, Inc. (NASDAQ: VYGR) climbed 10.6 percent to $18.54 following Q1 results. Blink Charging Co. (NASDAQ: BLNK) rose 10.4 percent to $5.739. Immersion Corporation (NASDAQ: IMMR) gained 9.6 percent to $12.69
• [By Ethan Ryder]

  MCBC Holdings (NASDAQ:MCFT) shares reached a new 52-week high and low during trading on Wednesday . The company traded as low as $30.42 and last traded at $30.27, with a volume of 14269 shares changing hands. The stock had previously closed at $29.28.

• [By Ethan Ryder]

  Shares of MCBC Holdings Inc (NASDAQ:MCFT) have received an average rating of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $28.08.

Top 10 Value Stocks To Invest In Right Now: Zimmer Biomet Holdings, Inc.(ZBH)

Advisors' Opinion:

• [By Max Byerly]

  Zimmer Biomet Holdings Inc (NYSE:ZBH) – Investment analysts at Oppenheimer lowered their Q3 2018 earnings estimates for Zimmer Biomet in a research note issued on Monday, July 30th. Oppenheimer analyst S. Lichtman now anticipates that the medical equipment provider will post earnings of $1.59 per share for the quarter, down from their previous estimate of $1.72. Oppenheimer has a “Buy” rating and a $138.00 price target on the stock. Oppenheimer also issued estimates for Zimmer Biomet’s Q4 2018 earnings at $2.22 EPS, FY2018 earnings at $7.64 EPS and FY2019 earnings at $7.97 EPS.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on Zimmer Biomet (ZBH)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  Massachusetts Financial Services Co. MA trimmed its holdings in shares of Zimmer Biomet (NYSE:ZBH) by 8.5% during the first quarter, HoldingsChannel reports. The institutional investor owned 15,053,800 shares of the medical equipment provider’s stock after selling 1,404,161 shares during the quarter. Massachusetts Financial Services Co. MA owned 0.07% of Zimmer Biomet worth $1,641,467,000 at the end of the most recent quarter.

• [By Joseph Griffin]

  Adviser Investments LLC acquired a new stake in Zimmer Biomet (NYSE:ZBH) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,318 shares of the medical equipment provider’s stock, valued at approximately $144,000.

• [By Max Byerly]

  Zimmer Biomet Holdings Inc (NYSE:ZBH) has been given a consensus rating of “Buy” by the thirty research firms that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, seventeen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $135.86.

• [By Stephan Byrd]

  IBM Retirement Fund trimmed its stake in shares of Zimmer Biomet (NYSE:ZBH) by 12.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,444 shares of the medical equipment provider’s stock after selling 620 shares during the period. IBM Retirement Fund’s holdings in Zimmer Biomet were worth $485,000 at the end of the most recent reporting period.

Top 10 Value Stocks To Invest In Right Now: SM Energy Company(SM)

Advisors' Opinion:

• [By Stephan Byrd]

  SM Energy (NYSE:SM) – Equities research analysts at Seaport Global Securities lifted their Q2 2018 earnings per share estimates for shares of SM Energy in a research report issued on Wednesday, May 23rd. Seaport Global Securities analyst M. Kelly now anticipates that the energy company will post earnings per share of ($0.08) for the quarter, up from their prior forecast of ($0.09). Seaport Global Securities also issued estimates for SM Energy’s Q3 2018 earnings at $0.00 EPS, FY2018 earnings at $0.06 EPS, Q1 2019 earnings at $0.00 EPS, Q2 2019 earnings at $0.06 EPS, Q3 2019 earnings at $0.35 EPS, Q4 2019 earnings at $0.48 EPS and FY2019 earnings at $0.89 EPS.

• [By Logan Wallace]

  Scotia Howard Weill upgraded shares of SM Energy (NYSE:SM) from a sector perform rating to a sector outperform rating in a research note published on Thursday morning.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on SM Energy (SM)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com